Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.78
CTIC's Cash to Debt is ranked higher than
65% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. CTIC: 3.78 )
CTIC' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 3.78

Equity to Asset 0.35
CTIC's Equity to Asset is ranked higher than
55% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CTIC: 0.35 )
CTIC' s 10-Year Equity to Asset Range
Min: -2.7   Max: 0.95
Current: 0.35

-2.7
0.95
F-Score: 6
Z-Score: -32.61
M-Score: 23.05
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -119.75
CTIC's Operating margin (%) is ranked higher than
68% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. CTIC: -119.75 )
CTIC' s 10-Year Operating margin (%) Range
Min: -123250   Max: -119.75
Current: -119.75

-123250
-119.75
Net-margin (%) -123.26
CTIC's Net-margin (%) is ranked higher than
67% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. CTIC: -123.26 )
CTIC' s 10-Year Net-margin (%) Range
Min: -169773.75   Max: -123.26
Current: -123.26

-169773.75
-123.26
ROE (%) -94.62
CTIC's ROE (%) is ranked higher than
56% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. CTIC: -94.62 )
CTIC' s 10-Year ROE (%) Range
Min: -293.4   Max: -29.18
Current: -94.62

-293.4
-29.18
ROA (%) -45.61
CTIC's ROA (%) is ranked higher than
62% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. CTIC: -45.61 )
CTIC' s 10-Year ROA (%) Range
Min: -280.23   Max: -26.43
Current: -45.61

-280.23
-26.43
ROC (Joel Greenblatt) (%) -758.05
CTIC's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. CTIC: -758.05 )
CTIC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2377.81   Max: -38.55
Current: -758.05

-2377.81
-38.55
Revenue Growth (%) 210.70
CTIC's Revenue Growth (%) is ranked higher than
100% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. CTIC: 210.70 )
CTIC' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 328.1
Current: 210.7

-100
328.1
EBITDA Growth (%) -52.90
CTIC's EBITDA Growth (%) is ranked higher than
52% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. CTIC: -52.90 )
CTIC' s 10-Year EBITDA Growth (%) Range
Min: -84   Max: 26.1
Current: -52.9

-84
26.1
EPS Growth (%) -59.50
CTIC's EPS Growth (%) is ranked higher than
53% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. CTIC: -59.50 )
CTIC' s 10-Year EPS Growth (%) Range
Min: -82.6   Max: 24.6
Current: -59.5

-82.6
24.6
» CTIC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CTIC Guru Trades in

CTIC Guru Trades in

Q4 2013

CTIC Guru Trades in Q4 2013

Jim Simons 285,747 sh (New)
» More
Q1 2014

CTIC Guru Trades in Q1 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CTIC



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about CTI Biopharma Corp

Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp and Dollar General Corp
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp. and Dollar General Corp. Read more...

Ratios

vs
industry
vs
history
P/B 15.70
CTIC's P/B is ranked higher than
59% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. CTIC: 15.70 )
CTIC' s 10-Year P/B Range
Min: 1.21   Max: 22.88
Current: 15.7

1.21
22.88
P/S 9.36
CTIC's P/S is ranked higher than
79% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. CTIC: 9.36 )
CTIC' s 10-Year P/S Range
Min: 0.01   Max: 288
Current: 9.36

0.01
288
EV-to-EBIT -7.24
CTIC's EV-to-EBIT is ranked lower than
51% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CTIC: -7.24 )
CTIC' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -7.24

Current Ratio 3.31
CTIC's Current Ratio is ranked higher than
70% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. CTIC: 3.31 )
CTIC' s 10-Year Current Ratio Range
Min: 0.38   Max: 24.99
Current: 3.31

0.38
24.99
Quick Ratio 3.03
CTIC's Quick Ratio is ranked higher than
70% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. CTIC: 3.03 )
CTIC' s 10-Year Quick Ratio Range
Min: 0.38   Max: 24.96
Current: 3.03

0.38
24.96

Valuation & Return

vs
industry
vs
history
Price/Net Cash 133.00
CTIC's Price/Net Cash is ranked higher than
73% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 65.19 vs. CTIC: 133.00 )
CTIC' s 10-Year Price/Net Cash Range
Min: 0.01   Max: 1427.57
Current: 133

0.01
1427.57
Price/Net Current Asset Value 66.50
CTIC's Price/Net Current Asset Value is ranked higher than
73% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. CTIC: 66.50 )
CTIC' s 10-Year Price/Net Current Asset Value Range
Min: 0.01   Max: 139.32
Current: 66.5

0.01
139.32
Price/Tangible Book 15.60
CTIC's Price/Tangible Book is ranked higher than
65% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. CTIC: 15.60 )
CTIC' s 10-Year Price/Tangible Book Range
Min: 0.01   Max: 105
Current: 15.6

0.01
105
Price/Median PS Value 5.20
CTIC's Price/Median PS Value is ranked higher than
65% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. CTIC: 5.20 )
CTIC' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 560
Current: 5.2

0.01
560
Forward Rate of Return (Yacktman) -355.23
CTIC's Forward Rate of Return (Yacktman) is ranked higher than
52% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. CTIC: -355.23 )
CTIC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -355.23

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:0QUJ.country, CTIC.Italy, CEPR.Germany
Cell Therapeutics, Inc. was incorporated in Washington in 1991. The Company is a biopharmaceutical company that develops, acquires and commercializes novel treatments for cancer. Its goal is to build a biopharmaceutical company with a diversified portfolio of proprietary oncology drugs. The Company's research, development, acquisition and in-licensing activities concentrate on identifying and developing new, less toxic and more ways to treat cancer. The Company is currently focusing on pixantrone, OPAXIO, and brostallicin. The Company is developing pixantrone, a novel anthracycline derivative, for the treatment of non-Hodgkin's lymphoma, or NHL, and various other hematologic malignancies, solid tumors and immunological disorders. Pixantrone was studied in its EXTEND, or PIX301, clinical trial, which is the first randomized, controlled, phase III single-agent clinical trial of pixantrone for patients with relapsed, aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The Company competes with pharmaceutical companies and with other specialized biotechnology companies, including Bristol-Myers Squibb Co., Sanofi-Aventis, Roche Group, Genentech, Inc., OSI Pharmaceuticals, Inc., Eli Lilly and Company, Abraxis, Neopharm Inc., Telik, Inc., TEVA Pharmaceuticals Industries Ltd. and PharmaMar. The Company is subject to federal, state and local laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain materials, biological specimens and wastes.
» More Articles for CTIC

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp and Dollar G Mar 24 2014 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
comment on CTIC Dec 16 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Feb 25 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Jan 28 2011 
Weekly CEO Sells Highlight: CTIC, DDR, UNM, BRCM, TC Jan 09 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 250,000 Shares Jan 03 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 200,000 Shares Dec 17 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 150,000 Shares Dec 10 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 100,000 Shares Nov 05 2010 

More From Other Websites
CTI BIOPHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jul 21 2014
CTI BioPharma Expands Access To PIXUVRI® With Approval In Israel And Add-on Reimbursement Status In... Jul 21 2014
CTI BioPharma Expands Access To PIXUVRI® With Approval In Israel And Add-on Reimbursement Status In... Jul 21 2014
NeoStem Awarded 2014 Cell Therapeutics Technology Leadership Award from Frost & Sullivan Jul 14 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jul 01 2014
CTI BioPharma Completes Recruitment in PERSIST-1 Pivotal Phase 3 Trial of Pacritinib for Patients... Jul 01 2014
CTI BioPharma Completes Recruitment in PERSIST-1 Pivotal Phase 3 Trial of Pacritinib for Patients... Jul 01 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jun 30 2014
BrainStorm Cell, Octane construct bioreactor prototype for NurOwn Jun 27 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jun 12 2014
CTI Announces United Kingdom National Cancer Research Institute AML Cooperative Group Initiates... Jun 12 2014
Israel stem cell developer BrainStorm names Fiorino as CEO Jun 08 2014
CTI BIOPHARMA CORP Financials Jun 04 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to... Jun 02 2014
Cell Therapeutics, Inc. Announces Change of Name to CTI BioPharma Corp. May 30 2014
CELL THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation... May 29 2014
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Cell... May 29 2014
CollabRx's Mobile App Simplifies Cancer Treatment Options May 29 2014
Cell Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference May 29 2014
CELL THERAPEUTICS INC Files SEC form 8-K, Material Modification to Rights of Security Holders,... May 22 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide